Weight loss is commonly recommended for treating obstructive sleep apnea (OSA) in those with obesity.^1,2 However, achieving and maintaining this weight loss is often difficult without bariatric surgery, and no approved anti-obesity medications have proven effective for OSA management.^1,2 Recently, the United States Food and Drug Administration (US FDA) approved tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, as the first pharmacological treatment for moderate-to-severe OSA in adults with obesity.¹ This approval, based on the results of the phase 3 SURMOUNT-OSA trial, introduces a new treatment option for sleep medicine, providing an alternative to traditional management methods such as positive airway pressure (PAP) therapy.¹

Despite being an established biomarker for heart failure, the utility of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in identifying broader complications, such as cardiorenal dysfunction, has remained underexplored.^1,2 This knowledge gap, particularly within Asian populations, has limited the ability of clinicians to stratify risk and intervene early in patients at the highest risk of adverse outcomes.¹ A retrospective cohort study utilizing the Hong Kong Diabetes Biobank (HKDB), led by researchers from the Department of Medicine and Therapeutics, The Chinese University of Hong Kong (CUHK) found NT-proBNP as a reliable biomarker for predicting cardiovascular and renal complications in patients with type 2 diabetes (T2DM).¹